StockNews.AI
COLL
StockNews.AI
187 days

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

1. Collegium Pharmaceutical to report Q4 and full-year 2024 results on February 27. 2. Live conference call scheduled for 4:30 PM ET after financial results are announced. 3. Company's portfolio includes pain management and ADHD treatments like Jornay PM. 4. Collegium is focused on growing commercial portfolio and disciplined capital deployment.

Earnings
-2.19%Current Return
VS
+1.12%S&P 500
$30.5302/13 08:05 AM EDTEvent Start
$29.8602/14 02:39 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings reports usually influence stock price positively. Strong products like Jornay PM may boost investor confidence.

How important is it?

Earnings announcements are crucial for potential valuation changes. Investors focus on this information for immediate decision-making.

Why Short Term?

Q4 earnings report impacts stock price immediately. Positive results will likely influence short-term trading activity.

Related Companies

JORN
February 13, 2025 08:00 ET  | Source: Collegium Pharmaceutical, Inc. STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com. Investor Contact: Danielle JesseDirector, Investor Relationsir@collegiumpharma.com Media Contact:Cheryl WheelerHead of Corporate Communicationscommunications@collegiumpharma.com

Related News